Notice: Fall 2017 exams affected by natural disasters... More >

Expand/Collapse Close

ABIM knows that we have many physicians whose lives have been upended by recent natural disasters. If you live or work near an affected area, we understand that the weather may have impacted your ability to take your Fall 2017 exam as scheduled. We have developed a series of options to help you get through this process as smoothly as possible. If you have any questions, please call us at 1-800-441-ABIM (2246) or email request@abim.org.

American Board of Internal Medicine home page

Initial Certification indicates that physicians have met rigorous standards through intensive study, accredited training and evaluation and that they have the clinical judgment, skills and attitudes essential for the delivery of excellent patient care.

MOC is a professionally determined standard that attests that an internist is staying current in knowledge and practice throughout his/her career.

For more than 75 years, Certification by ABIM has stood for the highest standard in internal medicine and its 20 subspecialties.

Cardiovascular Board Clinical Cardiac Electrophysiology Exam Committee

Bradley P. Knight, MD, Chair

Dr. Knight is board certified in Internal Medicine, Cardiovascular Disease and Clinical Cardiac Electrophysiology. At Northwestern Memorial Hospital, Dr. Knight is an attending cardiac electrophysiologist, Director of Cardiac Electrophysiology, Director of the Cardiac Electrophysiology Laboratory and Director of Electrocardiography. He is also the Medical Director for the Center of Heart Rhythm Disorders at the Bluhm Cardiovascular Institute. He is a Professor of Medicine at Northwestern University Feinberg School of Medicine and a member of the Northwestern Medical Faculty Foundation.

Dr. Knight joined the University of Michigan faculty in 1997 and then moved to the University of Chicago in 2002 where he was the Director of Cardiac Electrophysiology for seven years.

Considered an expert in the management of patients with heart rhythm disorders, Dr. Knight's clinical interests remain broad and include management of all types of heart rhythm disorders, and implantation of cardiac rhythm management devices such as pacemakers and defibrillators. His research interests include atrial fibrillation; catheter ablation for complex arrhythmias, including atrial fibrillation; intracardiac imaging techniques; diagnostic maneuvers used in the electrophysiology laboratory; the use of defibrillators in patients with syncope and a cardiomyopathy; sudden cardiac arrest; and pacing to improve heart failure. He has been an investigator for several multicenter clinical trials, and is on the editorial board of several major medical journals. He has published over 200 peer-reviewed manuscripts, reviews, case reports and editorials. He is currently the Editor of EP Lab Digest.

Dr. Knight is Chair of the American Board of Internal Medicine Cardiovascular Board Clinical Cardiac Electrophysiology Exam Committee. He is also an active member of the Heart Rhythm Society, American College of Cardiology and the American Heart Association.

Dr. Knight earned his bachelor's degree at the University of North Carolina, Chapel Hill in the School of Public Health, and his medical degree at The Ohio State University. He completed his training in medicine, cardiology and cardiac electrophysiology at the University of Michigan.

As of January 2017, Dr. Knight reported the following external relationships:

Funding for preclinical trial research staff, paid to Northwestern University, from the following company:

  • Medtronic Inc., for an institutional atrial fibrillation ablation database.

Service on data and safety monitoring boards for the following company, with honoraria:

  • Applied Clinical Intelligence LLC, for Neurologic and Sympathetic Safety Independent Adjudication Committee Charter.

Service on a research-related expert panel or advisory board for the following company, with compensation for travel expenses and honoraria:

  • Medtronic, for an Extravascular Advisory Panel.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with compensation as listed:

  • Agama Medical, for development of a catheter ablation tool for atrial fibrillation ablation.
  • Medtronic Inc., development of a subcutaneous defibrillator, receiving reimbursement for travel expenses and honoraria.

Providing FDA-required training in the use of devices with compensation as listed:

  • Medtronic Inc., participating in physician proctoring outside the United States and as required by the FDA in the United States on the use of the cryoballoon for the treatment of atrial fibrillation, receiving reimbursement for travel expenses and honoraria.

Work as an author or editor for following companies, with compensation as listed:

  • HMP Communications for EP Lab Digest, receiving compensation as an editor.
  • UpToDate, receiving compensation as an author and editor.

Dr. Knight serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Heart Association, Get With The Guidelines® Program Committee Member, without compensation.
  • Heart Rhythm Society, co-Chair of Education Committee, without compensation.

David J. Callans, MD

Dr. Callans is the Associate Director of Electrophysiology, University of Pennsylvania Health System and Professor of Medicine, Perelman School of Medicine at the University of Pennsylvania. He is board certified in Internal Medicine, Cardiovascular Disease and Cardiac Electrophysiology.

Prior to returning to the University of Pennsylvania, he practiced at the Medical College of Pennsylvania (MCP, 1996 to 1998) as an Associate Professor of Medicine at the MCP-Hahnemann School of Medicine and at Presbyterian Hospital as a Clinical Assistant Professor of Medicine at the University of Pennsylvania.

Dr. Callans is active in the Heart Rhythm Society, currently serving as the Chair of the Education committee, but he has also been involved in the Program Committee for the annual Scientific Sessions. He is a member of the American Board of Internal Medicine Cardiovascular Board Clinical Cardiac Electrophysiology Exam Committee. He is a fellow of the HeartRhythm Society, the American College of Cardiology and the American Heart Association.

Dr. Callans received his bachelor's degree in biological sciences from the University of Chicago (1982) and medical degree from Johns Hopkins University (1986). Postgraduate training in medicine, cardiology and cardiac electrophysiology was performed at the University of Pennsylvania.

As of April 2017, Dr. Callans reported the following external relationships:

Service on data and safety monitoring boards for the following companies, with compensation as listed:

  • Hansen Medical, for a trial of a robotic system for ablation of atrial fibrillation, receiving honoraria.
  • Impulse Dynamics, for a trial of cardiac contractility modulation for heart failure, receiving honoraria.
  • St. Jude Medical, for a trial of leadless pacemaker.

Dr. Callans also received honoraria from Abbott for research-related consulting.

  • Dr. Callans has received honoraria from Boston Scientific, Medtronic Inc, and St. Jude for lectures for fellows’ education courses.

Work as an author or editor for following companies, with compensation as listed:

  • UpToDate, receiving compensation as an editor.

Dr. Callans serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • Heart Rhythm Society, Board of Trustees member, without compensation.

Dr. Callans also serves on the Clinical Events Committee for Acutus Medical.

Emile Daoud, MD

Dr. Daoud is Professor, Internal Medicine at the Wexner Medical Center at The Ohio State University in Columbus, Ohio. He serves as the Chief of Cardiac Electrophysiology since 2007. He is board certified in Cardiovascular Disease and Clinical Cardiac Electrophysiology.

From 1998 to 2007, Dr. Daoud was Director of Electrophysiology Research with the Midwest Research Foundation and worked as a Clinical Electrophysiologist with MidOhio Cardiology at Riverside Methodist Hospital, before joining The Ohio State University in 2007. Prior to that, following fellowship training, he was Assistant Professor at the University of Michigan for three years before relocating to Columbus, Ohio.

Dr. Daoud has published more than 150 manuscripts, and has a particular interest in ablation of atrial and ventricular arrhythmias and device therapy, including biventricular pacing, subcutaneous defibrillators, and leadless pacing systems. He is currently a Fellow of the American College of Cardiology and a Fellow of the Heart Rhythm Society, as well as a member of the American Heart Association. He has been listed as America's Best Doctors in the U.S. News and World Report, a Top 10 faculty educator at The Ohio State University Medical Center, and has served on numerous national steering committees and advisory boards, including serving as a member of the American Board of Internal Medicine Cardiovascular Board Clinical Cardiac Electrophysiology Exam Committee.

Dr. Daoud received his undergraduate degree from University of Notre Dame, and his medical degree from the University of Cincinnati. He then completed internal medicine training at The Johns Hopkins Hospital (1988-1991) in Baltimore, Maryland, and cardiology fellowship and subspecialty training in electrophysiology at the University of Michigan (1991-1995) in Ann Arbor, Michigan.

As of January 2017, Dr. Daoud reported the following external relationships:

Funding for clinical trial expenses and staff, paid to The Ohio State University, from the following companies:

  • Medtronic, a trial of an implantable cardioverter defibrillator for ejection fraction.
  • St. Jude, for a trial on cardiac resynchronization therapy for non-left bundle branch block.
  • EBR Systems, for a trial of a plunge electrode for left ventricular pacing using ultrasound energy.

Dr. Daoud also reported receiving funding for a trial of ablation of persistent atrial fibrillation using a MRI fibrosis map. The study is supported by Siemens, St. Jude Medical, Biosense Webster, Boston Scientific, General Electric (GE) Healthcare and Medtronic.

Attendance at investigators’ meetings, with compensation for travel expenses and honoraria from the following companies:

  • Biosense Webster, for a trial on an irrigated circular ablation catheter for atrial fibrillation.
  • St. Jude, for a trial on cardiac resynchronization therapy for non-left bundle branch block.

Dr. Daoud serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • Heart Rhythm Society, Chair for Cardiac Implantable Electronic Devices Educational Committee, without compensation.

Nathan A. Mark Estes III, MD

Dr. Estes is Professor of Medicine at Tufts University School of Medicine and Director of the Cardiac Arrhythmia Service at Tufts Medical Center, Boston, Massachusetts. He is board certified in Internal Medicine, Cardiovascular Disease and Clinical Cardiac Electrophysiology.

Dr. Estes is a member of the American Board of Internal Medicine Cardiovascular Board Clinical Cardiac Electrophysiology Exam Committee and has served on the Examination Writing Committee for the International Board of Heart Rhythm Examiners. He has served as the President of the Boston Board and Northeast Affiliate of the American Heart Association (AHA), Chairman of the AHA Council on Clinical Cardiology, and President of the Heart Rhythm Society. Dr. Estes has co-Chaired the Performance Measure Writing Committee of the American College of Cardiology (ACC) and AHA Atrial Fibrillation Performance Measures. He has served on the Performance Measures Committee of the Heart Rhythm Society and on the Quality Metrics Task Force of the ACC.

Dr. Estes is the Editor-in-Chief of UpToDate in Cardiology. He has received multiple awards and honors, including being elected to Alpha Omega Alpha at the University of Cincinnati, the University of Pennsylvania Award of Merit, Moses Brown School Distinguished Achievement Award, the AHA Paul Dudley White Award and the Distinguished Leadership Award of the AHA. Dr. Estes also has been recognized with the President's Award of the Heart Rhythm Society (2013), the Distinguished Achievement Award of the European Cardiac Arrhythmia Society (2014) and the AHA Distinguished Achievement Award (2014).

Dr. Estes received his undergraduate degree from the University of Pennsylvania and and his medical degree from the University of Cincinnati. He completed medical training at the Deaconess Hospital, cardiology training at Tufts Medical Center, and clinical cardiac electrophysiology training at Massachusetts General Hospital.

As of January 2017, Dr. Estes reported the following external relationships:

Service on data and safety monitoring boards for the following company, without compensation:

  • Milestone Pharmaceuticals, Independent Data Management Committee member for a trial of a supraventricular tachycardia drug.

Work funded by educational grants from industry, paid to Dr. Estes, from the following companies:

  • Boston Scientific, receiving salary support for Director of educational course for fellows.
  • St. Jude, receiving salary support for Director of educational course for fellows.

Dr. Estes serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • Heart Rhythm Society, Chairman Ethics Committee, without compensation.

Paul A. Friedman, MD

Dr. Friedman is a Professor of Medicine and Vice Chair of the Department of Cardiovascular Medicine and Vice Chair for Academic Affairs and Faculty Development at Mayo Clinic, Rochester, Minnesota. He also serves as Medical Director for Remote Monitoring. He is board certified in Cardiovascular Disease and Clinical Cardiac Electrophysiology.

Previously, Dr. Friedman served as Director of the Cardiac Implantable Device Lab, Mayo Clinic. He is a trained electrical engineer, with deep experience in innovation (with more than 40 patents issued, he was named Minnesota Top Inventor), and scientific research (more than 250 scientific original publications). He is a member of the American Board of Internal Medicine Cardiovascular Board Clinical Cardiac Electrophysiology Exam Committee committed educator, serving as a director for five national and international meetings, editor of seven textbooks and author of more than 60 book chapters. He is a frequent visiting professor and lecturer at educational meetings.

Dr. Friedman earned a bachelor's degree in liberal arts and bachelor's degree in electrical engineering from the University of Texas at Austin. He received his medical degree from Stanford University, and trained in internal medicine at the University of Washington, Seattle and Stanford University. He trained in cardiovascular medicine and cardiac electrophysiology at Mayo Clinic.

As of January 2017, Dr. Friedman reported the following external relationships:

Attendance at investigators' meetings, with compensation for travel expenses and honoraria from the following companies:

  • Medtronic, for a clinical trial of an implantable cardioverter-defibrillator to detect atrial fibrillation.
  • St. Jude, for a steering committee for a clinical trial of a leadless pacemaker, paid to the Mayo Clinic.

Service on data and safety monitoring boards for the following company, with honoraria:

  • Boston Scientific, for a longitudinal study on device performance and for an Advanced Life Support study.

Service on a research-related expert panel or advisory board for the following companies, with compensation for travel expenses and/or honoraria:

  • Boston Scientific, for a cardiac rhythm management advisory board, receiving reimbursement for travel expenses and honoraria.
  • Medtronic, for an advisory board on the development of a novel defibrillator, receiving reimbursement for travel expenses.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with equity provided to the Mayo Clinic.

  • CardioThrive, for testing a novel form of a defibrillator.
  • Leadexx, for consulting on a clinical trial of a novel extraction tool.

Dr. Friedman holds a healthcare-related patent for a novel device to treat valvular heart disease, with income from Sorin.

Michael R. Gold, MD, PhD

Dr. Gold is currently the Michael E. Assey Professor of Medicine and Chief of Cardiology at the Medical University of South Carolina in Charleston. He is board certified in Internal Medicine, Cardiology and Clinical Cardiac Electrophysiology. Dr. Gold was previously the Director of Electrophysiology and Professor of Medicine at the University of Maryland.

Dr. Gold is currently the President of the Association of Professors of Cardiology and President of the Heart Rhythm Society. He is the Editor-in-Chief of Current Cardiology Risk Reports, an associate Editor-in-Chief of International Journal of Heart Rhythm, a section Editor for Heart Rhythm and a senior editor for the Journal of the American College of Cardiology. He also serves on the Editorial Board of The American Journal of Cardiology, Pacing and Clinical Electrophysiology, Journal of the American College of Cardiology Clinical Electrophysiology, Journal of Cardiovascular Electrophysiology and Current Cardiology Reports. He has published more than 200 peer-reviewed manuscripts. Dr. Gold is a member of the American Board of Internal Medicine Cardiovascular Board Clinical Cardiac Electrophysiology Exam Committee.

He received a doctoral degree in physiology from the University of Virginia and a medical degree from the University of Colorado. His postgraduate medical training in internal medicine and cardiology were at Massachusetts General Hospital and Harvard Medical School.

As of January 2017, Dr. Gold reported the following external relationships:

Funding for clinical trial expenses, paid to the Medical University of South Carolina, from the following company:

  • Boston Scientific, providing funding for a cardiac resynchronization therapy multicenter trial and a subcutaneous implantable cardioverter defibrillator trial.

Attendance at investigators' meetings, with compensation for travel expenses and honoraria from the following companies:

  • BioControl, for a clinical trial evaluating a system for the treatment of congestive heart failure, receiving compensation for travel expenses and honoraria.
  • Boston Scientific, for a subcutaneous implantable cardioverter defibrillator trial, receiving reimbursement for travel expenses.

Providing FDA-required training in the use of devices with compensation as listed:

  • Boston Scientific, participating in physician proctoring outside the United States and as required by the FDA in the United States on the use of a subcutaneous implantable cardioverter defibrillator, receiving reimbursement for travel expenses and honoraria.

Dr. Gold serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Association of Professors of Cardiology, President, without compensation.
  • Heart Rhythm Society, President and member of several committees, receiving reimbursement for travel expenses.

David E. Haines, MD

Dr. Haines is Professor of Cardiovascular Medicine at Oakland University-William Beaumont School of Medicine and the Director of the Heart Rhythm Center at Beaumont Health in Royal Oak, Michigan. He is also a former Director of the Clinical Cardiac Electrophysiology (CCEP) Fellowship program. He is board certified in Clinical Cardiac Electrophysiology, Cardiovascular Disease and Internal Medicine. He is a fellow of both the Heart Rhythm Society and the American College of Cardiology.

Previously, Dr. Haines was Professor of Medicine at the University of Virginia. At that institution, he was Director of the CCEP Fellowship program from 1989 to 2003 and Director of the Cardiovascular Fellowship Training Program from 1988 to 2002.

Dr. Haines is currently the President of the Intersocietal Accreditation Commission for Cardiac Electrophysiology and a member of the Cardiovascular Board Clinical Cardiac Electrophysiology Exam Committee of the American Board of Internal Medicine. He has served the Heart Rhythm Society (HRS) as Vice Chair of the Scientific and Clinical Documents Committee, Chair of the Fellowship and Training Committee, and on numerous other committees and task forces. Between 1999 and 2013, Dr. Haines was co-Chair of the HRS Board Review Course. Dr. Haines has also volunteered his services on several committees for the American College of Cardiology (ACC) and as the ACC Governor of Virginia.

Dr. Haines received his bachelor's degree from Williams College, Williamstown, Massachusetts, and his medical degree from the University of Rochester School of Medicine and Dentistry, Rochester, New York. He completed his internal medicine training at the University of Vermont, Burlington, Vermont, and his cardiology and clinical cardiac electrophysiology training at the University of Virginia, Charlottesville, Virginia.

As of January 2017, Dr. Haines reported the following external relationships:

Preclinical research, with funding paid to Beaumont Health, from the following companies:

  • Biosense Webster, for a study of advanced radiofrequency ablation technologies.
  • Medtronic, for a study of new ablation catheters.
  • Philips Medical Systems, for a study of intracardiac echocardiography.

Funding for clinical trial expenses and staff, paid to Beaumont Health, from the following companies:

  • ARCA biopharma, to evaluate bucindolol to prevent atrial fibrillation.
  • Boston Scientific, for a catheter ablation study.
  • Toray Medical Co., for a catheter ablation study.

Attendance at investigators' meetings, with compensation as listed, paid to Beaumont Health, from the following companies:

  • ARCA biopharma, for a meeting related to bucindolol, receiving reimbursement for travel expenses and honoraria.
  • Toray Medical Co., for a meeting related to catheter ablation, receiving reimbursement for travel expenses and honoraria.

Post-marketing clinical research, with funding for trial expenses and staff provided to Beaumont Health, from the following company:

  • St. Jude Children's Hospital, for a study of catheter ablation.

Service on other non-profit healthcare-related companies:

Dr. Haines serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Heart Rhythm Society, Chair of Corporate Relations Committee, without compensation.
  • Intersocietal Accreditation Commission, Board Member, receiving reimbursement for travel expenses, paid to Beaumont Health

Kalyanam Shivkumar, MD, PhD

Dr. Shivkumar is a physician scientist who serves as the Director of The University of California, Los Angeles (UCLA) Cardiac Arrhythmia Center and Clinical Cardiac Electrophysiology Program since the Arrhythmia Center's establishment in 2002. He is currently Professor of Medicine and has joint appointments in Radiology and Bioengineering.His field of specialization is interventional cardiac electrophysiology and he leads a group at UCLA that is involved in clinical care, teaching, research and biomedical innovation. The team provides state of the art clinical care, has developed several innovative techniques (e.g., epicardial mapping) for the non-pharmacological management of cardiac arrhythmias and other cardiac interventions. The team has a major focus on mechanistic research. Dr. Shivkumar's research work relates to mechanisms of cardiac arrhythmias in humans especially the role of the autonomic nervous system and neurovisceral sciences in general. The UCLA Neurocardiology Research Center of Excellence was established as the specialized research arm of the Arrhythmia Center in 2014.

Dr. Shivkumar has received several teaching awards and serves as a member of the American Board of Internal Medicine Cardiovascular Board Clinical Cardiac Electrophysiology Exam Committee. He has been elected to the membership of the American Society of Clinical Investigation (ASCI) and serves as the institutional representative of UCLA for the ASCI. He has also been elected as an honorary fellowship of the Royal College of Physicians.

Dr. Shivkumar received his medical degree from the University of Madras, India, in 1991 and his doctoral degree from UCLA in 2000. He completed his cardiology fellowship training at UCLA, and upon completion of his training joined the faculty at University of Iowa, where he also served as the Associate Director of Cardiac Electrophysiology.

As of January 2017, Dr. Shivkumar reported the following external relationships:

Preclinical research, with funding for research staff and expenses paid to the University of California, Los Angeles, from the following company:

  • GlaxoSmithKline, for a preclinical animal study for assessment of cardiac modulation by electrical blockade of nerves.

Funding for clinical trial expenses and staff, paid to the University of California, from the following company:

  • St. Jude, for a trial of catheter ablation.

Dr. Shivkumar holds a healthcare-related patent for FDA-approved products for the prevention of air embolism and stroke, with income from EP Dynamics, Inc. He is also the founder of EP Dynamics, Inc.

Dr. Shivkumar serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • Heart Rhythm Society, Publication Sub-Committee Member, Section Editor and Ambassador to India, without compensation.
  • International Society of Autonomic Neuroscience, North America Representative, without compensation.

Dr. Shivkumar also reported he serves as the Data and Safety Monitoring Board Chair for VytronUS.